PDLI Financial Facts

General and administrative expenses: 6.95M
Net income per basic share (in dollars per share): 0.03
See Full Income Statement

Cash and cash equivalents: 115.85M
Total stockholders' deficit: 738.65M
See Full Balance Sheet

PDL BioPharma, Inc. (PDLI) Earnings

  |   Expand Research on PDLI
Next EPS Date 11/4/16 *Est. EPS Growth Rate -80.9% *Last Qtr.
Average EPS % Beat Rate -0.4% Revenue Growth Rate -84.8% *Last Qtr.
Average % Move 1-Wk after EPS -8.3% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/4/16 Q216 $0.09$0.08 +$0.01$21M$33.46M N/A Details
5/4/16 Q116 $0.52$0.50 +$0.02$103.4M$142.05M N/A Details
2/22/16 Q415 $0.61$0.54 +$0.07$178.1M$149.2M N/A Details
11/4/15 Q315 $0.42$0.61 -$0.19$124.6M$164.8M N/A Details
8/5/15 Q215 $0.47$0.52 -$0.05$138.1M$137.75M N/A Details
5/6/15 Q115 $0.50$0.52 -$0.02$149.7M$140.8M N/A Details
2/23/15 Q414 $0.32$0.57 -$0.25$117.1M$158.15M N/A Details
11/10/14 Q314 $0.61$0.56 +$0.05$164.6M$165.1M N/A Details